Effects of Diabetogenic Agent Streptozotocin on Hematological Parameters of Wistar Albino Rats "An Experimental Study"

Akhtar Ali[1*], Shehla Shaheen[1], Zahida Memon[1], Faiza Agha[2],
Moazzam Ali Shahid[3] and Nisha Zahid[1]

[1]*Department of Pharmacology, Ziauddin Medical College, Ziauddin University, Pakistan.*
[2]*Department of Biochemistry, Liaqat National Medical College Karachi, Pakistan.*
[3]*Department of Research, Ziauddin Medical College, Ziauddin University, Pakistan.*

Authors' contributions

This work was carried out in collaboration among all authors. The concept of study, data analysis, drafting, and finalizing of the results were done by author AA. The article was critically reviewed and finally drafted by author SS. Finally reviewed and approved by author ZM. Laboratory/instrument based work was performed under the supervision of author MAS and assisted by authors FA and NZ. All authors read and approved the final manuscript.

Article Information

Original Research Article

ABSTRACT

Background: Diabetes mellitus has remained the major concern for medical sciences researches due to its deleterious effects on general, physical and mental health of patients. To understand the pathophysiology and to explore better treatment options for such kind of metabolic disorders it is necessary to generate the experimental animal models. To create diabetic animal models, streptozotocin has shown predominance in selectivity as a diabetogenic agent. While studying effects of any intervention in the diabetic animal models, being a cytotoxic drug streptozotocin may affect the study results by inhibiting highly replicating cells especially hematopoietic cells.

_____

*Corresponding author: E-mail: akhtar.ali@zu.edu.pk;

Aims: The aim of study was to analyze the effects of streptozotocin on various cellular components of blood such as RBCs, WBCs (Lymphocytes, Neutrophils, Eosinophils), Hb%, HCT and Platelets, at baseline, 5th day and 15th day without any intervention.

Study Design: Animal based Experimental study.

Place and duration of Study: The study was conducted at animal house of faculty of Pharmacy Ziauddin University Karachi, while laboratory work was performed at MDRL-1 Ziauddin University.

Methodology: In Group A normal saline and in group B and C 60 mg / kg streptozotocin diluted in normal saline was administered intraperitoneally. After the confirmation of induction of Diabetes in rats, on fifth day blood samples were drawn from Group A and B and were analyzed. While blood samples from group C were drawn on fifteenth day.

Results: Analysis of various hematological parameters on 5th day revealed that there was a decrease in the levels of Hb, HCT, RBCs and WBCs with an increase in platelet count in group B in comparison to group A (control). On the other hand, in Group C (15th day), blood cell counts (Hb, HCT, RBCs, WBCs, Lymphocytes, Neutrophils and platelets) seemed to recover from streptozotocin induced decline that was observed in group B, however did not reach the baselines as in group A(control).

Conclusion: It is concluded that change in hematological parameters of rats after administration of streptozotocin is reversible. The blood parameters may recover near to base line values without any intervention within two weeks.

1. INTRODUCTION

Diabetes mellitus has remained the major concern for medical sciences researches not only due to its high incidence and prevalence rate but also due its deleterious effects on general, physical and mental health of the patients [1]. To understand the pathophysiology and to explore better treatment options for such kind of metabolic disorders it is necessary to generate the experimental animal models [2]. To create diabetic animal models, surgical (pancreatectomy) and pharmacological (alloxan monohydrate and streptozotocin) options have been used in research but pharmacological options particularly use of streptozotocin has shown predominance in selectivity as a diabetogenic agent [1,2]. Chemically, streptozotocin is a derivative of synthetic Nitrosoureido Glucopyranose and has been used for cancer chemotherapies [3], being its potential to inhibit DNA synthesis in bacterial and mammalian cells [4]. While its diabetogenic effect is thought to be attributed to its ability to cause pancreatic β cells' death by DNA alkylation and hence used to induce diabetes mellitus in experimental animals [5,6].

The methods to induce diabetes in animal models by streptozotocin fall under three categories 1. Multiple small doses (i.e. 40 mg/kg) of streptozotocin over a period of several days 2. A single moderate dose (i.e. 60 mg/kg) of streptozotocin or 3. A single large dose (100 mg/kg) of streptozotocin produce diabetes in 48-72 hours. Usually a single large dose of streptozotocin is used to induce diabetes in experimental models as reported by Ito et al. 100 mg / kg of streptozotocin produced non-insulin dependent diabetes mellitus in experimental animals [7]. Streptozotocin can be administered by various routes including subcutaneous and intramuscular routes but intraperitoneal and intravenous administration routes are preferred. [8]. After 3-4 days of streptozotocin administration fasting blood glucose levels are obtained to confirm the accuracy of procedure [9] and on 5th day when 180-500 mg/dl serum glucose levels are obtained experimental animals are considered as diabetic [10].

Though streptozotocin is preferred pharmacological method for induction of diabetes [11], many studies have reported spontaneous recovery from hyperglycemia due to reactive hyperinsulinemia insulinoma [12,13,14]. Streptototozin, not only affects pancreas and cause diabetes in experimental animals but also have a potential to produce toxic effects on other body tissues as well. It has been learnt through a number of studies that streptozotocin is associated with high incidence of hepatic and renal tumors [15], increase in permeability of blood brain barrier [16], renal hypertrophy [17] and retinal damage in experimental animal models [18]. As already discussed that streptozotocin damages DNA by alkylation and produces free radicals, therefore it may harm any organ system of animals [19]. Despite of aforementioned, streptozotocin is still employed

in various researches for the induction of diabetes mellitus all over the world. While studying effects of any intervention (eg drugs, herbs, dietary modifications etc.) in the diabetic animal model, being a cytotoxic drug streptozotocin may affect the study results by inhibiting highly replicating cells especially hematopoietic cells. Moreover, it is also unknown whether streptozotocin induced changes are corrected over the time or permanent. Hence in order to achieve unbiased results in the diabetic model it is necessary to analyze the immediate and delayed effects of streptozotocin on various hematological parameters before any intervention. Therefore, this study was conducted to analyze the effects of streptozotocin on various cellular components of blood such as RBCs, WBCs (Lymphocytes, Neutrophils, Eosinophils), Hb%, HCT and Platelets, at baseline, 5th day and 15th day without any intervention.

2. MATERIALS AND METHODS

2.1 Study Design

It was an Animal based Experimental study.

2.2 Study Settings and Duration

The study was conducted at animal house of faculty of Pharmacy Ziauddin University Karachi, while laboratory work was performed at MDRL-1 Ziauddin University.

2.3 Animals

Eighteen, male wistar albino rats of 12 weeks' age, weighing 300- 400 g were purchased from Animal house of Agha Khan University.

2.4 Induction of Diabetes Mellitus

60 mg / kg (6 mg / 100 g) streptozotocin diluted in normal saline was administered intraperitoneally [20]. Rats were kept deprived of their feed and water for twelve hours before administration of streptozotocin. Blood glucose levels were obtained after 72 hours by using @Abbott Free Style Optium Xceed glucometer. Rats with blood glucose level >180 mg/dl were considered as diabetic.

Blood sample collection: 1 ml blood were drawn from lateral tail vein of all the rats in EDTA containing vacutainer tubes, and was transferred to MDRL-1 for the analysis of RBCs, WBCs, Hb, HCT, Platelets, Lymphocytes, Neutrophils and Eosinophils

Grouping of Animals: Animals were randomly selected for grouping.

Group A: Control group (streptozotocin untreated)

Group B: Streptozotocin Treated Diabetic Group 1(5th day)

Group C: Streptozotocin Treated Diabetic Group 2 (15th day)

Experiment: In Group A normal saline was administered intraperitoneally as this was our control group, and in group B and C 60 mg / kg (6 mg / 100 g) streptozotocin diluted in normal saline was administered intraperitoneally. After the confirmation of induction of Diabetes in rats, on fifth day blood samples were drawn from Group A and B and were analyzed. While blood samples from group C were drawn on fifteenth day and were analyzed by @sysmex automated cell counter.

2.5 Statistical Analysis

Data entry and analysis were conducted on SPSS version 20. Anova followed by post hoc tukey's test was applied for inter and intra group comparison of various hematological parameters. p-value less than 0.05 was considered as significant.

3. RESULTS

We found that after the administration 60mg/kg streptozotocin, diabetic profile was achieved in group B and C, when compared with controls with a significant p value (i.e. 0.000). Analysis of various hematological parameters on 5th day revealed that there was a decrease in the levels of Hb, HCT, RBCs and WBCs with an increase in platelet count in group B in comparison to group A (control). On the other hand, in Group C (15th day), blood cell counts (Hb, HCT, RBCs, WBCs, Lymphocytes, Neutrophils and platelets) seemed to recover from streptozotocin induced decline that was observed in group B, however did not reach the baselines as in group A(control) as shown in Table 1. While monocytes and eosinophils remained unchanged in Group C. Intergroup comparison of all animal groups showed significant p-values i.e.<0.05 for FBS,

Hb, HCT, RBCs, WBCs, Lymphocytes, Neutrophils and Platelets count, while the difference among all groups for Eosinophils and Monocytes was non-significant, p-values (1.00 and 0.905) respectively as shown in Fig. 1.

Table 1 Represents the means of variables (i.e. sum of values of all samples / n= 6) in all groups and p value after Anova. Graphical representation for each variable is shown through mean plots.

Following are the means plots of hematological parameters of Wistar albino rats.

Fig. 1. Hematocrit and differential leukocyte count of all the groups

Table 1. Means of variables in all groups

Hematological Parameter	Group A control (mean ± sd)	Group B STZ* treated 5th day (mean ± sd)	Group CSTZ* treated 15th day (mean ± sd)	p-value
FBS Levels (mg/dl)	79.83(± 8.7)	296.6(±24.8)	285.83(±8.9)	0.000
Hb (g/dl)	16 (± 1.2)	12.8(±1.1)	15(± 0.632)	0.000
RBCs x 10^6/ μl	10.41(± 0.81)	7.12 (± 0.35)	9.8 (± 0.46)	0.000
	8.85 x 10^3 (± 0.89)	6.95 x 10^3 (± 0.50)	8.41 x 10^3(± 0.86)	0.002
Platelets x 10^3 / μl	708.16 (± 16.4)	879.33 (± 30.14)	676.5 (± 26.48)	0.000

	HCT %	Lymphocytes	Neutrophills	Eosinphills	Monocytes
Control	39.50%	67.16%	30%	1.30%	3%
5th Day	34.16%	54.50%	41.50%	1.50%	2.33%
15th day	30.83%	54.50%	41.50%	1.50%	2.33%

Fig. 2. Hematocrit and Differential Leukocyte Count

4. DISCUSSION

Glucose is a basic fuel and an essential nutrient required by almost all body cells, its abnormal concentrations after administration of streptozotocin may lead to change in biochemical and hematological parameters of individuals [21]. Streptozotocin is highly recommended drug for induction of diabetes mellitus in animals [9,11] after its intraperitoneal administration hyper-glycemic profile was achieved at 60mg/kg dose in both the groups i.e. B and C. The results of our study (Table 1 group B) are parallel with the findings of many studies in which they have reported the decline of RBCs, WBCs and increase in platelet count after few days of administration of streptozotocin [22,23,24] whereas, at the same time our study is showing variation in group C (Table 1 group C). The findings in group C (15 days) are somehow different from the previous researches as they

have associated the recovery in cell count of blood parameters with different herbal and allopathic medications. In studies conducted by Verma N et., al and Colak S et al. they have attributed the reversal in blood parameters to Sapindus mukorossi Gaerten fruits & lichen extracts respecively [25,26] on the other hand, the results of our study found that the recovery in blood parameters is a normal phenomenon that can happen with the advancement of time. However in accordance to other studies, no major changes in the number of lymphocytes, monocytes and neutrophils were displayed in our study results [23,24]. It was observed in a study that the change in hematological parameters particularly in platelets is due to increase in blood viscosity that occur because of water deprivation before streptozotocin administration and change in glucose concentration after streptozotocin administration [27]. Yeom et al. in 2016 has highlighted that the change in hematological

parameters specially in platelets after administration of streptozotocin is not a direct effect that is produced in response to its administration but this change is attributed to change in environment of body of animals due to induction of diabetes [28]. It is seen that after administration of streptozotocin confirmation of diabetes mellitus is analyzed by glucometer [24, 26] and when the readings are found to be significant animal model is considered as a perfect diabetic model to carry out research, according to our study it is not true. As streptozotocin belongs to nitrosoureido glucopyranose group and it is used as chemotherapeutic agent it may impose its harmful effects on highly replicating cells including blood cells so there should be a base line level in all parameters at least after two weeks of streptozotocin administration for further intervention. According to our study it seems like that the recovery in blood parameters is a normal physiologic mechanism that is happening in the body of animals few days after the administration of streptozotocin and this reversal specially in hematological parameter should not be regarded as an attribution of any medication. This practice may give us biased results that can be a disaster in medical field because after animal based experimental trials humans based trails are the next step.

5. CONCLUSION

It is concluded that change in hematological parameters of rats after administration of streptozotocin is reversible. The blood parameters may recover near to base line values without any intervention within two weeks. Therefore, to get unbiased results after any intervention (drugs/herbs/alteration in diet etc.), the aforementioned should be administered at least two weeks after streptozotocin administration in diabetic model.

6. LIMITATIONS

In our study the major limitation was observation of animals for only 15 days and blood samples from three different animal groups (i.e. Control (A), Streptozotocin treated 5th (B) and 15th(C) days) were taken into consideration, rather than observing and following the same animal group on various days.

7. SUGGESTIONS

Further studies should be performed in which animals should be observed for more than 15

days. There should be a follow-up of single group with more than 10 animals and analyzation of hematological parameters of same animals should be performed on different days. We suggest that while working on diabetic animal models there must be a gap of 15 days after administration of streptozotocin to get unbiased results in further experiments. To rule out the mystery of this alteration we recommend animal based experimental trials to identify the molecular pathways responsible for decrease in hematological parameters after streptozotocin administration and their self-recovery from that declination period.

CONSENT

It is not applicable.

ETHICAL APPROVAL

The study was approved by Animal Ethics committee of Ziauddin University and Protocol No. 2018-003 was allotted. All the animals were given twelve-hour light and dark cycle, and before start of treatment animals were acclimatized with the environment. Animals were dealt through all procedures according to CARE guidelines 2010 [29].

ACKNOWLEDGEMENT

We are grateful to Dr. Farah Ahmed (Associate professor, Department of Community Medicine) for her unconditioned help and beneficial input on ethics of Animals and Data analyzation and Dr. Sadaf (In-charge Animal House and HOD, Department of Pharmacology, Faculty of Pharmacy) for her support and guidance regarding intervention and husbandry of Animals. We also appreciate Dr. Noor Israr, Dr. Shehzano (Lecturers Ziauddin Medical College) and Mr. Umar (Lab Assistant, Department of Pharmacology, Faculty of Pharmacy) for their help in sampling and laboratory procedures.

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

1. Federiuk IF, Casey HM, Quinn MJ, Wood MD, Ward KWJCm. Induction of type-1 diabetes mellitus in laboratory rats by use of alloxan: Route of administration, pitfalls,

and insulin treatment. J Comparative Medicine. 2004;54(3):252-7.

2. Thatte UJIjop. Still in search of a herbal medicine. Indian Journal of Pharmacology. 2009;41(1):1.

3. Srinivasan K, Ramarao PJIJoMR. Animal model in type 2 diabetes research: An overview. Indian Journal of Medical Research. 2007;125(3):451.

4. Holemans K, Aerts L, Van Assche FAJJotSfGI. Fetal growth restriction and consequences for the offspring in animal models. Journal of the Society for Gynecologic Investigation. 2003;10(7):392-9.

5. Szkudelski TJPr. The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas. J Physiological Research. 2001;50(6):537-46.

6. Lenzen SJD. The mechanisms of alloxan- and streptozotocin-induced diabetes. J Diabetologia. 2008;51(2):216-26.

7. Ito M, Kondo Y, Nakatani A, Naruse AJB, Bulletin P. New model of progressive non-insulin-dependent diabetes mellitus in mice induced by streptozotocin. J Biological Pharmaceutical Bulletin. 1999;22(9):988-9.

8. Tay YC, Wang Y, Kairaitis L, Rangan GK, Zhang C, Harris DCJKi. Can murine diabetic nephropathy be separated from superimposed acute renal failure? 2005; 68(1):391-8.

9. Akbarzadeh A, Norouzian D, Mehrabi M, Jamshidi S, Farhangi A, Verdi AA, et al. Induction of diabetes by streptozotocin in rats. Indian Journal of Clinical Biochemistry. 2007;22(2):60-4.

10. Etuk EJABJA. Animals models for studying diabetes mellitus. J Agric Biol JN Am. 2010;1(2):130-4.

11. Balamurugan A, Gu Y, Miyamoto M, Wang W, Inoue K, Tabata YJP. Streptozotocin (STZ) is commonly used to induce diabetes in animal models. J Pancreas. 2003;26:102-3.

12. Steiner H, Oelz O, Zahnd G, Froesch EJD. Studies on islet cell regeneration, hyper-plasia and intrainsular cellular inter-relations in long lasting streptozotocin diabetes in rats. 1970;6(6):558-64.

13. Yamagami T, Miwa A, Takasawa S, Yamamoto H, Okamoto HJCr. Induction of rat pancreatic B-cell tumors by the combined administration of streptozotocin or alloxan and poly (adenosine diphosphate ribose) synthetase inhibitors. 1985;45(4):1845-9.

14. Iwase M, Nunoi K, Wakisaka M, Kikuchi M, Maki Y, Sadoshima S, et al. Spontaneous recovery from non-insulin-dependent diabetes mellitus induced by neonatal streptozotocin treatment in spontaneously hypertensive rats. 1991;40(1):10-4.

15. Kazumi T, Yoshino G, Fujii S, Baba SJCr. Tumorigenic action of streptozotocin on the pancreas and kidney in male Wistar rats. 1978;38(7):2144-7.

16. Huber JD, VanGilder RL, Houser KAJAJoPH, Physiology C. Streptozotocin-induced diabetes progressively increases blood-brain barrier permeability in specific brain regions in rats. American Journal of Physiology-Heart Circulatory Physiology; 2006.

17. Olbricht CJ, Geissinger B, Gutjahr EJKi. Renal hypertrophy in streptozotocin diabetic rats: Role of proteolytic lysosomal enzymes. 1992;41(4):966-72.

18. Crouch R, Kimsey G, Priest D, Sarda A, Buse MJD. Effect of streptozotocin on erythrocyte and retinal superoxide dismutase. 1978;15(1):53-7.

19. Bolzán AD, Bianchi MSJMRRiMR. Geno-toxicity of streptozotocin. 2002;512(2-3): 121-34.

20. Jiao Y, Wang X, Jiang X, Kong F, Wang S, Yan CJJoe. Antidiabetic effects of *Morus alba* fruit polysaccharides on high-fat diet- and streptozotocin-induced type 2 diabetes in rats. Journal of Ethnopharmacology. 2017;199:119-27.

21. Singh M, Shin S. Changes in erythrocyte aggregation and deformability in diabetes mellitus: A brief review; 2009.

22. Onderoglu S, Sozer S, Erbil KM, Ortac R, Lermioglu FJJoP. Pharmacology. The evaluation of long-term effects of cinnamon bark and olive leaf on toxicity induced by streptozotocin administration to rats. 1999; 51(11):1305-12.

23. Oyedemi S, Adewusi E, Aiyegoro O, Akinpelu DJAPjotb. Antidiabetic and haematological effect of aqueous extract of stem bark of *Afzelia africana* (Smith) on streptozotocin–induced diabetic Wistar rats. 2011;1(5):353-8.

24. Sellamuthu PS, Arulselvan P, Fakurazi S, Kandasamy MJPJPS. Beneficial effects of mangiferin isolated from Salacia chinensis on biochemical and hematological parameters in rats with streptozotocin-induced diabetes. 2014;27(1):161-7.

25. Verma N, Amresh G, Sahu P, Mishra N, Singh AP, Rao CVJAPjotm. Antihyper-

glycemic activity, antihyperlipedemic activity, haematological effects and histo-pathological analysis of Sapindus mukorossi Gaerten fruits in streptozotocin induced diabetic rats. 2012; 5(7):518-22.

26. Çolak S, Geyikoğlu F, Aslan A, Deniz GYJT, health i. Effects of lichen extracts on haematological parameters of rats with experimental insulin-dependent diabetes mellitus. 2014;30(10):878-87.

27. Cho YI, Mooney MP, Cho DJJJods, technology. Hemorheological disorders in diabetes mellitus. 2008;2(6):1130-8.

28. Yeom E, Byeon H, Lee SJJSr. Effect of diabetic duration on hemorheological properties and platelet aggregation in streptozotocin-induced diabetic rats. 2016; 6:21913.

29. Council NR. Guide for the care and use of laboratory animals: National Academies Press; 2010.

Peer-review history:
The peer review history for this paper can be accessed here:
http://www.sdiarticle3.com/review-history/50653